| Year |
Citation |
Score |
| 2024 |
Chua C, Mahamed D, Nkongolo S, Sanchez Vasquez JD, Mehrotra A, Wong DKH, Chung RT, Feld JJ, Janssen HLA, Gehring AJ. Liver-restricted Type I IFN Signature Precedes Liver Damage in Chronic Hepatitis B Patients Stopping Antiviral Therapy. Journal of Immunology (Baltimore, Md. : 1950). PMID 38294274 DOI: 10.4049/jimmunol.2300569 |
0.383 |
|
| 2023 |
Genshaft AS, Subudhi S, Keo A, Sanchez Vasquez JD, Conceição-Neto N, Mahamed D, Boeijen LL, Alatrakchi N, Oetheimer C, Vilme M, Drake R, Fleming I, Tran N, Tzouanas C, Joseph-Chazan J, ... ... Gehring AJ, et al. Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients. Hepatology (Baltimore, Md.). PMID 37158243 DOI: 10.1097/HEP.0000000000000438 |
0.347 |
|
| 2023 |
Nkongolo S, Mahamed D, Kuipery A, Sanchez Vasquez JD, Kim SC, Mehrotra A, Patel A, Hu C, McGilvray I, Feld JJ, Fung S, Chen D, Wallin JJ, Gaggar A, Janssen H, ... Gehring AJ, et al. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells. The Journal of Clinical Investigation. 133. PMID 36594467 DOI: 10.1172/JCI158903 |
0.39 |
|
| 2022 |
Santer DM, Li D, Ghosheh Y, Zahoor MA, Prajapati D, Hansen BE, Tyrrell DLJ, Feld JJ, Gehring AJ. Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nature Communications. 13: 6992. PMID 36385011 DOI: 10.1038/s41467-022-34709-4 |
0.424 |
|
| 2022 |
Casey JL, Dore GJ, Grebely J, Matthews GV, Cherepanov V, Martinello M, Marks P, Janssen HLA, Hansen BE, Kaul R, MacParland SA, Gehring AJ, Feld JJ. Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection. Journal of Viral Hepatitis. PMID 36302162 DOI: 10.1111/jvh.13761 |
0.305 |
|
| 2022 |
Zahoor MA, Kuipery A, Mosa AI, Gehring AJ, Feld JJ. HepG2-NTCP Subclones Exhibiting High Susceptibility to Hepatitis B Virus Infection. Viruses. 14. PMID 36016422 DOI: 10.3390/v14081800 |
0.339 |
|
| 2022 |
Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, ... ... Gehring A, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nature Reviews. Gastroenterology & Hepatology. PMID 35859026 DOI: 10.1038/s41575-022-00649-z |
0.309 |
|
| 2022 |
Hoogeveen RC, Dijkstra S, Bartsch LM, Drescher H, Aneja J, Robidoux MP, Cheney JA, Timm J, Gehring A, Fonseca de Sousa PS, Ximenez L, Peliganga LB, Pitts A, Blackburn FE, Boonstra A, et al. Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen infection. Journal of Hepatology. PMID 35716846 DOI: 10.1016/j.jhep.2022.05.041 |
0.44 |
|
| 2022 |
Gehring AJ. Using Immunomodulatory and Antiviral Strategies in the Quest to Cure Hepatitis B Virus Infection. Gastroenterology & Hepatology. 18: 162-165. PMID 35506004 |
0.307 |
|
| 2022 |
Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology (Baltimore, Md.). PMID 34990029 DOI: 10.1002/hep.32314 |
0.365 |
|
| 2021 |
Kuipery A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, Janssen HLA, Gehring AJ. Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP. Hepatology (Baltimore, Md.). PMID 34743340 DOI: 10.1002/hep.32230 |
0.465 |
|
| 2020 |
Chua CG, Mehrotra A, Mazzulli T, Wong DK, Feld JJ, Janssen HLA, Gehring AJ. Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. Scientific Reports. 10: 11344. PMID 32647116 DOI: 10.1038/S41598-020-68226-5 |
0.496 |
|
| 2020 |
Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. Antiviral Research. 104816. PMID 32387476 DOI: 10.1016/J.Antiviral.2020.104816 |
0.463 |
|
| 2020 |
Mehrotra A, D'Angelo JA, Romney-Vanterpool A, Chu T, Bertoletti A, Janssen HLA, Gehring AJ. IFN-α Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation. The Journal of Infectious Diseases. PMID 32049318 DOI: 10.1093/Infdis/Jiaa064 |
0.503 |
|
| 2019 |
Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, et al. A global scientific strategy to cure hepatitis B. The Lancet. Gastroenterology & Hepatology. PMID 30981686 DOI: 10.1016/S2468-1253(19)30119-0 |
0.458 |
|
| 2019 |
Feld JJ, Gehring AJ. Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. Nature Reviews. Gastroenterology & Hepatology. PMID 30617296 DOI: 10.1038/S41575-018-0101-Y |
0.364 |
|
| 2019 |
Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 156: 325-337. PMID 30367834 DOI: 10.1053/J.Gastro.2018.10.032 |
0.474 |
|
| 2019 |
Addy I, Jambrecina A, Berg T, Bömmel Fv, Kropeit D, Vank C, Bigge A, Nedoschinsky K, Stobernack H, Rangaraju M, Kummer S, Matschl U, Gehring A, Eberhard J, Altfeld M, et al. FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis Journal of Hepatology. 70. DOI: 10.1016/S0618-8278(19)30944-2 |
0.308 |
|
| 2017 |
Gehring AJ. New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. Best Practice & Research. Clinical Gastroenterology. 31: 337-345. PMID 28774416 DOI: 10.1016/J.Bpg.2017.05.004 |
0.389 |
|
| 2017 |
Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, ... ... Gehring AJ, et al. Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. Science Immunology. 2. PMID 28567448 DOI: 10.1126/Sciimmunol.Aai7616 |
0.432 |
|
| 2016 |
Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. Journal of Hepatology. 64: S60-70. PMID 27084038 DOI: 10.1016/J.Jhep.2016.01.028 |
0.493 |
|
| 2015 |
Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, Urbani S, Chong YS, Guccione E, Bertoletti A. Trained immunity in newborn infants of HBV-infected mothers. Nature Communications. 6: 6588. PMID 25807344 DOI: 10.1038/Ncomms7588 |
0.444 |
|
| 2015 |
Qasim W, Brunetto M, Gehring AJ, Maini MK, Bonino F, Stauss H, Bertoletti A. Reply to: "To target or not to target viral antigens in HBV related HCC?". Journal of Hepatology. 62: 1450-2. PMID 25711420 DOI: 10.1016/J.Jhep.2015.02.026 |
0.361 |
|
| 2015 |
Gehring AJ, Ann D'Angelo J. Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cellular & Molecular Immunology. 12: 283-91. PMID 25363524 DOI: 10.1038/Cmi.2014.95 |
0.497 |
|
| 2015 |
Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Journal of Hepatology. 62: 486-91. PMID 25308176 DOI: 10.1016/J.Jhep.2014.10.001 |
0.469 |
|
| 2014 |
King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. Plos One. 9: e101904. PMID 25051027 DOI: 10.1371/Journal.Pone.0101904 |
0.514 |
|
| 2014 |
Gehring AJ, Bertoletti A, Tavis JE. Host factor-targeted hepatitis B virus therapies Intervirology. 57: 158-162. PMID 25034483 DOI: 10.1159/000360938 |
0.424 |
|
| 2014 |
Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, De Libero G, Gehring AJ, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. Plos Pathogens. 10: e1004210. PMID 24967632 DOI: 10.1371/Journal.Ppat.1004210 |
0.473 |
|
| 2014 |
Banu N, Chia A, Ho ZZ, Garcia AT, Paravasivam K, Grotenbreg GM, Bertoletti A, Gehring AJ. Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections. Scientific Reports. 4: 4166. PMID 24566718 DOI: 10.1038/Srep04166 |
0.493 |
|
| 2014 |
Hong LWM, Sandalova E, Gehring AJ, Chong Y-, Bertoletti A. P645 Trained Immunity In Neonates Of Hbv-Infected Mothers Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60807-2 |
0.355 |
|
| 2013 |
Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Wu Howland S, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. Molecular Therapy. Nucleic Acids. 2: e114. PMID 28173945 DOI: 10.1038/mtna.2013.43 |
0.437 |
|
| 2013 |
Bertoletti A, Gehring AJ. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? Plos Pathogens. 9: e1003784. PMID 24367255 DOI: 10.1371/Journal.Ppat.1003784 |
0.475 |
|
| 2013 |
Tavis JE, Gehring AJ, Hu Y. How further suppression of virus replication could improve current HBV treatment. Expert Review of Anti-Infective Therapy. 11: 755-7. PMID 23977931 DOI: 10.1586/14787210.2013.814846 |
0.343 |
|
| 2013 |
Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Molecular Therapy. Nucleic Acids. 2: e114. PMID 23941866 DOI: 10.1038/Mtna.2013.43 |
0.518 |
|
| 2013 |
Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A, Lim SG, Ferrari C, Ginhoux F, Bertoletti A. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. The Journal of Clinical Investigation. 123: 3766-76. PMID 23908113 DOI: 10.1172/Jci66043 |
0.552 |
|
| 2013 |
Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 3142-52. PMID 23447689 DOI: 10.4049/Jimmunol.1203218 |
0.429 |
|
| 2013 |
Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HL, Leong HN, Hadrup SR, Gehring AJ, Tan YJ, Bertoletti A, Grotenbreg GM. Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. European Journal of Immunology. 43: 1109-20. PMID 23280567 DOI: 10.1002/Eji.201243088 |
0.489 |
|
| 2013 |
King T, Gehring A, Bertoletti A, Ho Z, Delaney W, Subramanian M, McHutchison J, Guo Z, Lu Y, U'Ren L, Mann D, Bellgrau D, Apelian D. 370 WHOLE RECOMBINANT YEAST THERAPEUTIC VACCINE GENERATES HBV X, S, AND CORE ANTIGEN-SPECIFIC RESPONSES IN MURINE AND HUMAN T CELLS Journal of Hepatology. 58: S153. DOI: 10.1016/S0168-8278(13)60372-4 |
0.402 |
|
| 2013 |
Jo J, Tang X-, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, Bertoletti A. 55 Selective Activation Of Intrahepatic Immunity With Tlr8 Agonist: A Potent Therapeutic Strategy To Boost Antiviral Immunity In Human Liver Journal of Hepatology. 58. DOI: 10.1016/S0168-8278(13)60057-4 |
0.367 |
|
| 2012 |
Low JL, Naidoo A, Yeo G, Gehring AJ, Ho ZZ, Yau YH, Shochat SG, Kranz DM, Bertoletti A, Grotenbreg GM. Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes. Plos One. 7: e51397. PMID 23251518 DOI: 10.1371/Journal.Pone.0051397 |
0.485 |
|
| 2012 |
Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, Wasan PS, Wang XN, Malinarich F, Malleret B, Larbi A, Tan P, Zhao H, Poidinger M, Pagan S, ... ... Gehring A, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity. 37: 60-73. PMID 22795876 DOI: 10.1016/J.Immuni.2012.04.012 |
0.376 |
|
| 2011 |
Gehring AJ, Koh S, Chia A, Paramasivam K, Chew VS, Ho ZZ, Lee KH, Maini MK, Madhavan K, Lim SG, Bertoletti A. Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection. Plos One. 6: e23330. PMID 21876747 DOI: 10.1371/Journal.Pone.0023330 |
0.529 |
|
| 2011 |
Oh HL, Chia A, Chang CX, Leong HN, Ling KL, Grotenbreg GM, Gehring AJ, Tan YJ, Bertoletti A. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. Journal of Virology. 85: 10464-71. PMID 21813600 DOI: 10.1128/JVI.05039-11 |
0.362 |
|
| 2011 |
Chew SL, Or MY, Chang CX, Gehring AJ, Bertoletti A, Grotenbreg GM. Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads. The Journal of Biological Chemistry. 286: 28466-75. PMID 21680737 DOI: 10.1074/Jbc.M111.262691 |
0.373 |
|
| 2011 |
Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. Journal of Virology. 85: 1935-42. PMID 21159876 DOI: 10.1128/Jvi.01990-10 |
0.539 |
|
| 2011 |
Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology. 55: 103-10. PMID 21145860 DOI: 10.1016/J.Jhep.2010.10.025 |
0.518 |
|
| 2011 |
Gehring A, Jo J, Ho ZZ, Konduru S, Bertoletti A. 282 Effect Of The Hbv Pres2 Mutant On T Cell Recognition Of Hepatocyte Tumor Cell Lines Journal of Hepatology. 54. DOI: 10.1016/S0168-8278(11)60284-5 |
0.411 |
|
| 2011 |
Gehring A, Haniffa M, Konduru S, Ginhoux F, Bertoletti A. 281 Antigen Presenting Cells In The Circulation Of Chronic Hbv Patients Do Not Constitutively Cross-Present Hbv Antigens Journal of Hepatology. 54. DOI: 10.1016/S0168-8278(11)60283-3 |
0.457 |
|
| 2010 |
Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, Bertoletti A. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. Journal of Hepatology. 52: 330-9. PMID 20137825 DOI: 10.1016/J.Jhep.2009.12.015 |
0.451 |
|
| 2010 |
Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. Journal of Hepatology. 52: 370-9. PMID 19720422 DOI: 10.1016/J.Jhep.2009.07.013 |
0.381 |
|
| 2010 |
Gehring AJ, Xue S-, Ho ZZ, Teoh DYL, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. 88 Engineering Virus-Specific T Cell Immunity To Target Chronic Hepatitis B Virus Infection And Hbv-Related Hepatocellular Carcinoma Journal of Hepatology. 52. DOI: 10.1016/S0168-8278(10)60090-6 |
0.511 |
|
| 2010 |
Sastry KS, Too CT, Kaur K, Low L, Gehring A, MacAry P, Bertoletti A. 11 T Cell Receptor-Like Antibodies Targeting Hbv Infected Hepatocytes: A New Tool For Drug Delivery And Pathogenic Studies Journal of Hepatology. 52. DOI: 10.1016/S0168-8278(10)60013-X |
0.432 |
|
| 2009 |
Bertoletti A, Tan AT, Gehring AJ. HBV-Specific Adaptive Immunity. Viruses. 1: 91-103. PMID 21994540 DOI: 10.3390/V1020091 |
0.519 |
|
| 2009 |
Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Review of Gastroenterology & Hepatology. 3: 561-569. PMID 19817676 DOI: 10.1586/Egh.09.48 |
0.47 |
|
| 2009 |
Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 137: 682-90. PMID 19394336 DOI: 10.1053/J.Gastro.2009.04.045 |
0.478 |
|
| 2008 |
Kennedy PT, Gehring AJ, Nowbath A, Selden C, Quaglia A, Dhillon A, Dusheiko G, Bertoletti A. The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis. Journal of Viral Hepatitis. 15: 901-9. PMID 19087227 DOI: 10.1111/J.1365-2893.2008.01049.X |
0.512 |
|
| 2008 |
Tan AT, Loggi E, Boni C, Chia A, Gehring AJ, Sastry KS, Goh V, Fisicaro P, Andreone P, Brander C, Lim SG, Ferrari C, Bihl F, Bertoletti A. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. Journal of Virology. 82: 10986-97. PMID 18799575 DOI: 10.1128/Jvi.01124-08 |
0.536 |
|
| 2008 |
Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. The Journal of Clinical Investigation. 118: 1835-45. PMID 18398508 DOI: 10.1172/Jci33402 |
0.527 |
|
| 2008 |
Tavakoli S, Mederacke I, Herzog-Hauff S, Glebe D, Grün S, Strand D, Urban S, Gehring A, Galle PR, Böcher WO. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clinical and Experimental Immunology. 151: 61-70. PMID 18031557 DOI: 10.1111/J.1365-2249.2007.03547.X |
0.524 |
|
| 2008 |
Gehring AJ, Xue SA, Lim SG, Maini MK, Stauss H, Bertoletti A. 561 Reconstitution Of Hbv Specific Immunity Via Retroviral Gene Transfer Of A Hbv Core Specific T Cell Receptor In Chronic Hepatitis B Patients Journal of Hepatology. 48. DOI: 10.1016/S0168-8278(08)60563-2 |
0.504 |
|
| 2008 |
Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. 328 Hierarchy Of Tumor And Virus-Specific Cd8 T Cell Responses In Hbv-Infected Patients With Hepatocarcinoma Journal of Hepatology. 48. DOI: 10.1016/S0168-8278(08)60330-X |
0.493 |
|
| 2007 |
Bertoletti A, Gehring A. Immune response and tolerance during chronic hepatitis B virus infection. Hepatology Research. 37. PMID 17931183 DOI: 10.1111/J.1872-034X.2007.00221.X |
0.471 |
|
| 2007 |
Gehring AJ, Sun D, Kennedy PT, Nolte-'t Hoen E, Lim SG, Wasser S, Selden C, Maini MK, Davis DM, Nassal M, Bertoletti A. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. Journal of Virology. 81: 2940-9. PMID 17202217 DOI: 10.1128/Jvi.02415-06 |
0.532 |
|
| 2007 |
Loggi E, Tan AT, Boni C, Ho ZZ, Fisicaro P, Hua L, Fortini C, Chua W, Chisholm JV, Gehring AJ, Grandini E, Andreone P, Brander C, Lim SG, Ferrari C, et al. [407] Comprehensive Analysis Of Hbv Genotype-Specific T Cell Response In Genetically Different Populations Persistently Infected With Hbv Genotype B Or D Journal of Hepatology. 46. DOI: 10.1016/S0168-8278(07)62005-4 |
0.437 |
|
| 2007 |
Bertoletti A, Kennedy P, Gehring AJ. Role of the immune response in hepatitis B: Determinants of severity, chronicity, and response to antiviral therapy Liver Immunology: Principles and Practice. 179-191. DOI: 10.1007/978-1-59745-518-3_15 |
0.325 |
|
| 2006 |
Rojas RE, Thomas JJ, Gehring AJ, Hill PJ, Belisle JT, Harding CV, Boom WH. Phosphatidylinositol mannoside from Mycobacterium tuberculosis binds alpha5beta1 integrin (VLA-5) on CD4+ T cells and induces adhesion to fibronectin. Journal of Immunology (Baltimore, Md. : 1950). 177: 2959-68. PMID 16920931 DOI: 10.4049/Jimmunol.177.5.2959 |
0.61 |
|
| 2006 |
Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. Journal of Immunology (Baltimore, Md. : 1950). 177: 422-9. PMID 16785538 DOI: 10.4049/Jimmunol.177.1.422 |
0.588 |
|
| 2006 |
Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. The Journal of General Virology. 87: 1439-49. PMID 16690908 DOI: 10.1099/Vir.0.81920-0 |
0.503 |
|
| 2006 |
Gehring AJ, Kennedy PTF, Sun D, Hoen EN, Lim S, Wasser S, Selden C, Maini MK, Davis DM, Nassal M, Bertoletti A. O.058 Impact of human hepatocyte MHC-class I antigen presentation on virus-specific CD8 T cell function Journal of Clinical Virology. 36. DOI: 10.1016/S1386-6532(06)80063-6 |
0.461 |
|
| 2006 |
Kennedy PTF, Gehring A, Patch D, Selden C, Rees M, Williams R, Dusheiko G, Bertoletti A. 55 Activation of effector CD8+ T cells in the liver tissue microenvironment in patients with chronic viral hepatitis Journal of Hepatology. 44. DOI: 10.1016/S0168-8278(06)80056-5 |
0.473 |
|
| 2005 |
Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. Journal of Virology. 79: 3322-8. PMID 15731226 DOI: 10.1128/Jvi.79.6.3322-3328.2005 |
0.474 |
|
| 2004 |
Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. Journal of Immunology (Baltimore, Md. : 1950). 173: 2660-8. PMID 15294983 DOI: 10.4049/Jimmunol.173.4.2660 |
0.581 |
|
| 2003 |
Canaday DH, Gehring A, Leonard EG, Eilertson B, Schreiber JR, Harding CV, Boom WH. T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. Journal of Immunological Methods. 281: 129-42. PMID 14580887 DOI: 10.1016/J.Jim.2003.07.004 |
0.606 |
|
| 2003 |
Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infection and Immunity. 71: 4487-97. PMID 12874328 DOI: 10.1128/Iai.71.8.4487-4497.2003 |
0.592 |
|
| 2003 |
Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE, Torres M. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis (Edinburgh, Scotland). 83: 98-106. PMID 12758197 DOI: 10.1016/S1472-9792(02)00054-9 |
0.495 |
|
| Show low-probability matches. |